SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+0.65%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$660M
AUM Growth
+$660M
(-9.7%)
Cap. Flow
-$73.1M
Cap. Flow
% of AUM
-11.08%
Top 10 Holdings %
Top 10 Hldgs %
49.85%
Holding
121
New
21
Increased
35
Reduced
19
Closed
35
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$18.8M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$11.7M |
| 3 |
Stoke Therapeutics
STOK
|
$9.72M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$9.39M |
| 5 |
Verint Systems
VRNT
|
$9.07M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$31.2M |
| 2 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
$27.7M |
| 3 |
Novo Nordisk
NVO
|
$20.9M |
| 4 |
Viatris
VTRS
|
$11.5M |
| 5 |
Novartis
NVS
|
$9.61M |
Sector Composition
| 1 | Healthcare | 77.74% |
| 2 | Technology | 12.98% |
| 3 | Industrials | 2.53% |
| 4 | Consumer Discretionary | 2.11% |
| 5 | Communication Services | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Johnson & Johnson
JNJ
$427B
| $55.7M | 7.62% | 400,000 +135,000 | +51% | +$18.8M |
|
|
ALXN
2
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $44.1M | 6.03% | 336,800 +89,500 | +36% | +$11.7M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $42.2M | 5.77% | 929,900 +50,000 | +6% | +$2.27M |
|
4
Merck
MRK
$210B
| $37.9M | 5.18% | 452,000 +75,000 | +20% | +$6.29M |
|
5
AstraZeneca
AZN
$248B
| $31.8M | 4.35% | 770,000 +70,000 | +10% | +$2.89M |
|
6
Amicus Therapeutics
FOLD
$2.34B
| $31.3M | 4.29% | 2,510,320 +22,242 | +0.9% | +$278K |
|
|
7
Verint Systems
VRNT
$1.23B
| $23.3M | 3.18% | 432,552 +168,626 | +64% | +$9.07M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $23.1M | 3.16% | 250,000 | – | – |
|
9
GSK
GSK
$79.9B
| $20M | 2.74% | 500,000 +70,000 | +16% | +$2.8M |
|
|
ARQL
10
DELISTED
Arqule Inc
ARQL
| $19.6M | 2.69% | 1,782,643 +350,000 | +24% | +$3.85M |
|
11
UroGen Pharma
URGN
$900M
| $11.1M | 1.52% | 308,377 | – | – |
|
12
SolarEdge
SEDG
$2.01B
| $10.8M | 1.48% | 172,762 +53,695 | +45% | +$3.35M |
|
13
Travere Therapeutics
TVTX
$1.56B
| $10.7M | 1.46% | 530,678 +95,000 | +22% | +$1.91M |
|
|
RETA
14
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $10.6M | 1.46% | 112,769 +31,000 | +38% | +$2.92M |
|
|
15
Stoke Therapeutics
STOK
$1.08B
| $9.72M | 1.33% | +350,944 | New | +$9.72M |
|
|
BLUE
16
DELISTED
bluebird bio
BLUE
| $9.54M | 1.31% | 75,000 -8,796 | -10% | -$1.12M |
|
|
17
Regeneron Pharmaceuticals
REGN
$61.5B
| $9.39M | 1.28% | +30,000 | New | +$9.39M |
|
|
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $9.23M | 1.26% | 116,000 +16,000 | +16% | +$1.27M |
|
19
Ascendis Pharma
ASND
$11.8B
| $8.5M | 1.16% | 73,773 +5,500 | +8% | +$633K |
|
20
Caesarstone
CSTE
$49.1M
| $8.09M | 1.11% | 538,316 +60,202 | +13% | +$905K |
|
21
Wave Life Sciences
WVE
$1.53B
| $8.04M | 1.1% | +307,967 | New | +$8.04M |
|
22
Amazon
AMZN
$2.44T
| $7.95M | 1.09% | 4,200 +1,200 | +40% | +$2.27M |
|
|
23
Viatris
VTRS
$12.3B
| $7.62M | 1.04% | 400,000 -602,307 | -60% | -$11.5M |
|
24
Teva Pharmaceuticals
TEVA
$21.1B
| $7.33M | 1% | 793,834 +740,000 | +1,375% | +$6.83M |
|
25
Microsoft
MSFT
$3.77T
| $7.2M | 0.98% | 53,741 -7,656 | -12% | -$1.03M |
|